Clinical Trial Update: A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial is evaluating the combination of MEDI5752 and Axitinib in adults with advanced renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)
• MEDI5752

Snippet

Sponsor: MedImmune LLC | Conditions: Advanced Renal Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING